This list is based on the watchlists of people on Stock Events who follow P0F.STU. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
About
Egetis Therapeutics AB (publ), a pharmaceutical company, engages in the development and commercialization of orphan drugs in Sweden and internationally. It develops Aladote, which is in Phase IIb/III clinical trial for the treatment of paracetamol/acetaminophen overdosing and for the prevention of acute liver failure in paracetamol poisoning; and Emcitate, which is in Phase IIb clinical trial for the treatment of monocarboxylate transporter 8 deficiency. The company was formerly known as PledPharma AB (publ) and changed its name to Egetis Therapeutics AB (publ) in December 2020. Egetis Therapeutics AB (publ) was incorporated in 2006 and is headquartered in Stockholm, Sweden.
What is Egetis Therapeutics AB stock price today?▼
The current price of P0F.STU is €0.48 EUR — it has increased by +0% in the past 24 hours. Watch Egetis Therapeutics AB stock price performance more closely on the chart.
What is Egetis Therapeutics AB stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Egetis Therapeutics AB stocks are traded under the ticker P0F.STU.
Is Egetis Therapeutics AB stock price growing?▼
P0F.STU stock has risen by +2.35% compared to the previous week, the month change is a -16.52% fall, over the last year Egetis Therapeutics AB has showed a +34.08% increase.
When is the next Egetis Therapeutics AB earnings date?▼
Egetis Therapeutics AB is going to release the next earnings report on August 21, 2026.
In which sector is Egetis Therapeutics AB located?▼
Egetis Therapeutics AB operates in the Other sector.
When did Egetis Therapeutics AB complete a stock split?▼
Egetis Therapeutics AB has not had any recent stock splits.